Genomic Valley Biotech Ltd Stock Price Today (NSE: GVBL)
Fundamental Score
Genomic Valley Biotech Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Genomic Valley Biotech Ltd share price today is ₹24.25, up +0.00% on NSE/BSE as of 17 February 2026. Genomic Valley Biotech Ltd (GVBL) is a Small-cap company in the Biotechnology sector with a market capitalisation of ₹8.81 (Cr). The 52-week high for GVBL share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 88.14x, GVBL is currently trading above its industry average P/E of 51.82x. The company has a Return on Equity (ROE) of 9.68% and a debt-to-equity ratio of 0.00.
Genomic Valley Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Genomic Valley Biotech Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Genomic Valley Biotech Share Price: A Financial Analysis
The biotechnology sector is experiencing a period of rapid innovation, particularly in precision medicine, demanding astute capital allocation for sustained growth. This analysis delves into the current financial standing of Genomic Valley Biotech Ltd, focusing on its key metrics and comparing it to its peers. The Genomic Valley Biotech share price currently sits at ₹24.02, with a Price-to-Earnings (PE) ratio of 88.14 and a Return on Capital Employed (ROCE) of 11.83%. This analysis forms part of a wider 80-parameter fundamental audit, verified by Sweta Mishra.
The high PE ratio of 88.14 suggests that the market has high expectations for Genomic Valley Biotech's future earnings growth. However, it also indicates that the stock may be overvalued compared to its current earnings. Assessing the sustainability of this valuation requires careful examination of its growth prospects and competitive advantages.
Genomic Valley Biotech's ROCE of 11.83% reveals the company's efficiency in generating profits from its capital investments. This figure is crucial in determining the strength of the company's economic moat. A consistent ROCE above the cost of capital indicates a competitive advantage, as it suggests that the company can profitably reinvest earnings and generate higher returns. However, within the context of the broader biotechnology landscape, maintaining a competitive ROCE demands consistent R&D investment and operational efficiency.
Comparing Genomic Valley Biotech Ltd to its peers, such as
Advanced Enzyme Technologies Ltd, reveals differences in management quality and strategic direction. While we do not offer an opinion, observation of Advanced Enzyme Technologies Ltd often highlights their well-regarded management team, which is known for its focus on operational excellence and strategic acquisitions. Examining Genomic Valley Biotech's management strategy and its track record of capital allocation is crucial to understanding its potential for long-term value creation. Analyzing management's decisions and the company's ability to adapt to the rapidly evolving biotechnology landscape is key to forming a comprehensive view.Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Genomic Valley Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GVBL across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (20.70%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (9.68%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 88.14x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-100.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-57.14%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-0.24% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (4.42% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (4.42% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Genomic Valley Biotech Ltd Financial Statements
Comprehensive financial data for Genomic Valley Biotech Ltd including income statement, balance sheet and cash flow
About GVBL (Genomic Valley Biotech Ltd)
Genomic Valley Biotech Ltd (GVBL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Biotechnology sector with a current market capitalisation of ₹8.81 (Cr). Genomic Valley Biotech Ltd has delivered a Return on Equity (ROE) of 9.68% and a ROCE of 11.83%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking GVBL share price can monitor key metrics including P/E ratio, promoter holding of 46.72%, and quarterly earnings growth.
Company Details
Key Leadership
GVBL Share Price: Frequently Asked Questions
What is the current share price of Genomic Valley Biotech Ltd (GVBL)?
As of 17 Feb 2026, 10:10 am IST, Genomic Valley Biotech Ltd share price is ₹24.25. The GVBL stock has a market capitalisation of ₹8.81 (Cr) on NSE/BSE.
Is GVBL share price Overvalued or Undervalued?
GVBL share price is currently trading at a P/E ratio of 88.14x, compared to the industry average of 51.82x. Based on this relative valuation, the Genomic Valley Biotech Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of GVBL share price?
The 52-week high of GVBL share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Genomic Valley Biotech Ltd share price?
Key factors influencing GVBL share price include quarterly earnings growth (Sales Growth: -57.14%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Genomic Valley Biotech Ltd a good stock for long-term investment?
Genomic Valley Biotech Ltd shows a 5-year Profit Growth of 4.42% and an ROE of 9.68%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in GVBL shares.
How does Genomic Valley Biotech Ltd compare with its industry peers?
Genomic Valley Biotech Ltd competes with major peers in the Biotechnology. Investors should compare GVBL share price P/E of 88.14x and ROE of 9.68% against the industry averages to determine competitive standing.
What is the P/E ratio of GVBL and what does it mean?
GVBL share price has a P/E ratio of 88.14x compared to the industry average of 51.82x. Investors pay ₹88 for every ₹1 of annual earnings.
How is GVBL performing according to Bull Run's analysis?
GVBL has a Bull Run fundamental score of 24.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GVBL belong to?
GVBL operates in the Biotechnology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Genomic Valley Biotech Ltd share price.
What is Return on Equity (ROE) and why is it important for GVBL?
GVBL has an ROE of 9.68%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Genomic Valley Biotech Ltd generates profits from shareholders capital.
How is GVBL debt-to-equity ratio and what does it indicate?
GVBL has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is GVBL dividend yield and is it a good dividend stock?
GVBL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Genomic Valley Biotech Ltd shares.
How has GVBL share price grown over the past 5 years?
GVBL has achieved 5-year growth rates of: Sales Growth -0.24%, Profit Growth 4.42%, and EPS Growth 4.42%.
What is the promoter holding in GVBL and why does it matter?
Promoters hold 46.72% of GVBL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Genomic Valley Biotech Ltd.
What is GVBL market capitalisation category?
GVBL has a market capitalisation of ₹9 crores, placing it in the Small-cap category.
How volatile is GVBL stock?
GVBL has a beta of N/A. A beta > 1 suggests the Genomic Valley Biotech Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GVBL operating profit margin trend?
GVBL has a 5-year average Operating Profit Margin (OPM) of 20.70%, indicating the company's operational efficiency.
How is GVBL quarterly performance?
Recent quarterly performance shows Genomic Valley Biotech Ltd YoY Sales Growth of -57.14% and YoY Profit Growth of -100.00%.
What is the institutional holding pattern in GVBL?
GVBL has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Genomic Valley Biotech Ltd stock.